Increasingly, corporations in the health care and life sciences industries are supplementing their own internal research and development and business development efforts by participating in the equity funding of start-up and early stage companies which may over time be able to provide the corporation’s business with potential strategic and sometimes even financial gain.
In order to effectively and efficiently deliver practical legal and business advice to the investment professionals within a corporate strategic investor, in-house counsel advising on these matters must be sure to consider a variety of issues unique to these types of transactions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
